Financials Overview
263.15
3.35
(1.29%)
07/17/2026
Ascendis Pharma A/S (ASND)Overview
- Growth: Revenue of USD 691.71M in FY 2025, +90.2% YoY (+207.1% 4y CAGR).
- Profitability: gross 85.1% (-275 bps YoY) · operating -18.9% (+5,774 bps) · net -31.7% (+7,231 bps).
- Earnings: Net income -USD 219.03M (-42.1% YoY); EPS -3.62 (-44.6% YoY).
- Cash generation: Operating cash flow USD 51.77M; FCF USD 43.62M (6.3% of revenue), converting -20% of net income to cash.
- Capital Allocation: CapEx intensity 1.2% of revenue; dividends paid n/a (0% payout).
- Balance sheet: total debt USD 871.41M · cash USD 615.78M · net debt USD 255.64M · D/E -5.35x · net debt/EBITDA -2.2x.
- Returns on capital: ROE 134.6% · ROA -16.8%.
- Quality / risk: Altman Z 4.54 (safe) · Piotroski F 5/9 (mid).
- Fundamental rating: Overall B- (Neutral).
Rating Fundamentals
DefinitionsOverallNeutral
ROEStrong Buy
ROAStrong Buy
DEStrong Sell
PESell
PBStrong Sell
DCFStrong Sell
Scorecard
Overall Rating
B-
Neutral
DCF
Strong Sell
Altman Z-Score
4.54
Piotroski Score
5 / 9
Market Cap
USD 16.21B
Latest Revenue
USD 691.71M
FY 2025
Latest Net Income
-USD 219.03M
FY 2025
Stock Financial Scores
Definitions| Altman Z-Score | Piotroski Score | Working Capital | Total Assets | Retained Earnings | EBIT | Market Cap | Total Liabilities | Revenue |
| 4.5423 | 5.00 | -4,427,612 | 2,005,368,182 | -2,086,495,701 | -5,025,060 | 14,100,154,423 | 1,516,886,285 | 867,514,348 |
Key Financials
Revenue & Earnings
EPS
Gross & Operating Income
EBITDA
Cash Flow
Dividends Paid
Debt
Cash & Equivalents
Total Assets & Liabilities
Stockholders Equity
R&D and SG&A
Depreciation & Amortization